Paid Clinical Trials Rapid City
Discover 18 paid clinical trials in Rapid City, South Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
KHK4951Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
Sponsor:
Kyowa Kirin Co., Ltd.
Location:
Code:
NCT06116890
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Eligibility Criteria
Sex: All
Age: 50+
Healthy Volunteers: Not accepted
Interventions
KHK4951
Aflibercept Injection
LunsekimigA Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Sponsor:
Sanofi
Location:
Code:
NCT06790121
Conditions
Dermatitis Atopic
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Lunsekimig
Placebo
Wawokiya InterventionLiving Well With Serious Illness "Wicokuje Sica Tuha Akisniya Wiconi": Wawokiya Health Advocate Intervention
Sponsor:
Massachusetts General Hospital
Location:
Code:
NCT05208606
Conditions
Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Accepted
Interventions
Wawokiya Health Advocate
AmlitelimabA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Sponsor:
Sanofi
Location:
Code:
NCT06181435
Conditions
Dermatitis Atopic
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Amlitelimab
Placebo
KHK4951Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
Sponsor:
Kyowa Kirin Co., Ltd.
Location:
Code:
NCT06116916
Conditions
Diabetic Macular Edema (DME)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
KHK4951
Aflibercept Injection
Atezolizumab & Multi-Kinase InhibitorAtezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Sponsor:
Academic and Community Cancer Research United
Location:
Code:
NCT05168163
Conditions
Locally Advanced Hepatocellular Carcinoma
Metastatic Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma AJCC v8
Stage IIIA Hepatocellular Carcinoma AJCC v8
Stage IIIB Hepatocellular Carcinoma AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Atezolizumab
Cabozantinib
Lenvatinib
PegcetacoplanA Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sponsor:
Apellis Pharmaceuticals, Inc.
Location:
Code:
NCT06161584
Conditions
Geographic Atrophy
Eligibility Criteria
Sex: All
Age: 60+
Healthy Volunteers: Not accepted
Interventions
Pegcetacoplan
RetatrutideA Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06859268
Conditions
Obesity
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Retatrutide
Placebo
Atopic DermatitisA Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
Sponsor:
AbbVie
Location:
Code:
NCT06718101
Conditions
Atopic Dermatitis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Lutikizumab
Placebo
Drug-Eluting RegistryDrug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
Sponsor:
Boston Scientific Corporation
Location:
Code:
NCT04674969
Conditions
Peripheral Vascular Diseases
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.